The Italy National Research Council (CNR) has confirmed that the eye-controlled device used in March 2026 by a terminally ill woman to self-administer a lethal drug can be replicated for other patients, potentially breaking a key impasse in the country's access to medically assisted suicide. The 10,000-euro prototype, paid for by the Tuscan health authority, was designed specifically for "Libera," a 55-year-old woman with multiple sclerosis who became the first person in Italy to use such technology—yet its scalability could now reshape the landscape for immobilized patients seeking end-of-life autonomy.
Why This Matters
• Replicable design: The CNR device can be mass-produced and adapted for different disability profiles, according to the agency's ICT engineering director.
• Cost transparency: At 10,000 euros per unit, the device falls outside commercial medical device categories and was funded directly by the regional health authority.
• Political gridlock: Italy's Senate has indefinitely shelved the Bazoli bill on end-of-life rights, leaving patients dependent on regional initiatives and court orders rather than national legislation.
• Legal ambiguity: The device is not classified as a medical device by the Italy Ministry of Health, skirting regulatory pathways and raising questions about future procurement.
The Technology Behind the Tuscan Case
Emilio Campana, director of the CNR Department of ICT Engineering, testified before the Italian Senate's Justice Committee on June 30, 2026, that the eye-tracking apparatus developed for Libera was never intended as a one-off prototype. "The device is reproducible, it is adaptable to the patient, and this was planned from the outset," he told senators. "It was designed to identify whether the patient's will is present—it does not substitute for that will, but enables its realization and expression."
The tribunal in Florence had ordered the CNR to design and deliver the device after the local health authority struggled to source appropriate equipment. Initially, CNR President Andrea Lenzi had informed lawmakers that no suitable instruments existed for immobilized individuals to self-administer medications in assisted dying procedures, a statement that generated controversy when Campana's team later delivered a functioning device.
In a note sent to the Florence court—one that Campana says President Lenzi approved—the research body outlined the feasibility of "rapidly developing several identical copies of the device to be made available to local health authorities or the Italy National Health Service (SSN) for the most common types of conditions and disabilities."
A Custom Device or Medical Equipment?
Campana was explicit in distinguishing the apparatus from conventional medical technology. "The Italy Ministry of Health and the State Attorney's Office, representing the ministry and the Prime Minister's Office, state that this is not a medical device," he said. Instead, he characterized it as a "custom-made device"—fabricated once, authorized by a specific legal authority, for a single purpose and a single person.
He pushed back against the notion that this could be treated as a commercial product. "This is the State that, in compliance with the Constitutional Court ruling, must develop this tool for people who have the right but lack the physical capacity to realize that right." That framing shifts responsibility from the private sector to public health infrastructure, a politically charged distinction in a country where the SSN is already strained by funding shortages.
The 10,000-euro price tag, while modest compared to many medical technologies, was borne entirely by the Tuscan Northwest Local Health Authority (ASL Toscana Nord Ovest). Whether other regional health systems will fund similar devices—or whether the national government will establish a standardized procurement pathway—remains unanswered as the Senate debate drags on.
Parliamentary Paralysis and Regional Patchwork
Italy's legislative stalemate on end-of-life law has left a vacuum that regions and courts are struggling to fill. On June 3, 2026, the Senate approved a "suspensive motion" proposed by the center-right majority, sending the Bazoli bill back to the joint Justice and Social Affairs committees. Opposition lawmakers and civil society groups interpreted the move as a deliberate strategy to "bury" the legislation before the end of the current parliamentary term.
Public opinion polls consistently show that more than 70% of Italians support legal euthanasia, and over 80% back living wills (testamento biologico). Yet the governing coalition—comprising Fratelli d'Italia (FdI), Lega, and Forza Italia—has resisted codifying assisted dying into national law. FdI, the largest party in Prime Minister Giorgia Meloni's government, argues that the State should prioritize palliative care and family support rather than institutionalizing assisted suicide within the SSN.
Forza Italia has attempted to carve out a middle path. In May and June 2026, the party tabled amendments proposing that doctors could voluntarily and without pay assist patients in assisted suicide, even in public facilities, provided such services remain outside the essential levels of care (LEA) guaranteed by the SSN. This compromise, reportedly encouraged by Marina Berlusconi, seeks to reconcile religious and ethical objections with patients' constitutional rights as defined by the Constitutional Court.
Meanwhile, regions have taken matters into their own hands. Sardinia passed its own assisted suicide law in September 2025, only to have it challenged by the national government on constitutional grounds. Tuscany, Emilia-Romagna, and other regions are drafting or implementing regional frameworks to fill the legislative void, creating a patchwork of access rights that vary dramatically depending on where a patient lives.
The Constitutional Court's Ongoing Role
The Italy Constitutional Court remains the de facto arbiter of end-of-life rights. On June 23, 2026, the Court convened for its eighth session on the topic, this time focusing on the definition of "life-sustaining treatment"—one of the four conditions required under the Court's 2019 ruling (Case 242/2019, also known as the Cappato-Antoniani decision) for a patient to access assisted suicide.
The central question: Does "life-sustaining treatment" include only mechanical ventilation and artificial nutrition, or does it extend to continuous personal assistance for basic functions like eating, dressing, and moving? Expanding the definition would significantly broaden the pool of eligible patients, potentially including those with advanced ALS, paralysis, or degenerative neurological conditions who depend on caregivers rather than machines.
Both patients and advocacy groups testified at the June hearing, with some arguing for a broader interpretation to prevent discrimination against those whose suffering is equally intolerable but not mechanically sustained, and others warning that loosening criteria could erode protections for vulnerable individuals.
What This Means for Patients and Health Authorities
For residents navigating Italy's fragmented end-of-life landscape, the CNR testimony offers both promise and uncertainty. The device exists, it works, and it can be replicated—but no procurement protocol, funding mechanism, or national distribution plan has been established.
Patients who meet the Constitutional Court's criteria and obtain court approval may still face a logistical lottery: whether their regional health authority will fund and source the device, whether trained personnel are available, and whether political opposition at the local level will delay or obstruct implementation.
The case of "Irene," a 72-year-old woman from Naples with ALS, underscores the stakes. Like Libera, she has been deemed eligible for assisted suicide but lacks the physical ability to self-administer medication. Whether she will gain access to a CNR-style device depends on a tangle of regional politics, court orders, and the willingness of local health authorities to act in the absence of national guidance.
A System Waiting for Clarity
Italy's approach to assisted dying remains caught between constitutional mandate and legislative inertia. The CNR has demonstrated that technical solutions exist, yet the political will to integrate them into the public health system has not materialized. Until Parliament acts—or the Constitutional Court issues further clarifying rulings—patients, families, and health professionals will continue navigating a legal and bureaucratic maze where rights exist on paper but remain inaccessible in practice.
For now, the 10,000-euro eye-tracking device sits as both a symbol of what is possible and a reminder of how far Italy has yet to go in translating judicial precedent into lived reality.
